Nonsteroidal antiinflammatory drugs(NSAIDs) are known as clinically effective agents for treatment of inflammatory diseases. Inhibition of cyclooxygenase has been thought to be a major facet of the pharmacological mechanism of NSAIDs. However, it is difficult to ascribe the antiinflammatory effects of NSAIDs solely to the inhibition of prostaglandin synthesis. Human neutrophil elastase (HNElastase; HNE, EC 3.4.21.37) has been known as a causative factor in inflammatory diseases. To investigate the specific relationship between HNElastase inhibition and specificity of molecular structure of several NSAIDs, HNElastase was purified by Ultrogel AcA54 gel filtration, CM-Sephadex ion exchange, and HPLC (with TSK 250 column) chromatography. HNElastase was inhibited by aspirin and salicylate in a competative manner and by naproxen, ketoprofen, phenylbutazone, and oxyphenbutazone in a partial competative manner, but not by ibuprofen and tolmetin. 
Introduction
Human neutrophil elastase (HNElastase, EC 3.4.21.37) , is a causative factor in inflammatory diseases such as emphysema and rheumatoid arthritis (Janoff, 1972; Oholson and Olsson, 1977; Starkey, 1980; Fritz et al., 1986; Abramsom & Weissman, 1989) , HNElastases are regulated by plasma proteinase inhibitors such as alpha lproteinase inhibitor and alpha 2 -macroglobulin (Janoff, 1972; Oholson and Olsson, 1977; Starkey, 1980; Fritz et al., 1986) . Nonsteroidal antiinflammatory drugs (NSAIDs) are known as clinically effective agents for treatment of inflammatory diseases such as rheumatoid arthritis (Lentin et al., 1987; Vane et al., 1987 and 1995; Insel, 1996) . The mechanism of action has been known that NSAIDs inhibited cyclooxygenase (Vane et al., 1987 and 1995; Insel, 1996) . However, it is difficult to ascribe the antirheumatoid effects of aspirin-like drugs solely to the inhibition of prostaglandin synthesis (Insel, 1996) since HNElastase shows different sensitivity to the NSAIDs (Kang et al., 1996) . Specific interaction between the enzyme and the individual drug may be present. Total amino acid sequence of HNElastase was reported by Sinha (Sinha et al., 1987) and Bode (Bode et al., 1986) . Navia (Navia et al., 1989) reported the X-ray crystallographic structure. In comparison with other methods including IR or NMR, it is reasonable to investigate the mechanism of drug action by conformational change of the elastase-drug complex with Raman spectroscopic method. Since this method has the special advantage with only a small interference from the main biological solvent, water (Keller et al., 1994) . In this paper, we describe the characteristics of HNElastase inhibition by NSAIDs. We also propose a possible molecular, pharmacological inhibition mechanism of HNElastase by phenylbutazone according to the analysis of Raman spectroscopic data and visualized molecular model of human neutrophil elastase.
Materials and Methods

Materials
N-Succinyl-Ala-Ala-Ala-p-nitroanilide (SANA), N-succinylAla-Ala-Pro-Phe-p-nitroanilide (SAPNA), oxyphenbutazone, phenylbutazone, ibuprofen, salicylate, aspirin, ketoprofen, ibuprofen, tolmetin, indomethacin, sulindac, and Hypaque-Ficoll were Sigma products. Tris, glycine, and sodium dodecyl sulfate were Bio-Rad products. Ultrogel AcA54 and CM-Sephadex C-25 were Pharmacia products. Spectro pore 2 dialysis membrane was a product of Spectrum Medical Industries INC., L.A., U.S.A.. PM 10 ultrafiltration membrane was the product of Amicon Co.. All other chemicals were of the highest quality obtainable.
Purification of human neutrophil elastases
Human neutrophils were isolated from whole blood (acquired from the blood bank of Kosin Medical Center) by Ficoll-hypaque step gradient centrifugation at 200 × g for 20 min and washed three times with 50 mM Tris-Cl buffer, pH 7.3 (Voyum, 1968; Jeung et al., 1987) .
The method of purification of HNElastase was a modified method by Baugh and Travis (1976) . In brief, isolated neutrophils were suspended in 0.5 M Tris-Cl buffer, pH 7.3, containing 1.5 M NaCl and 50 mM CaCl 2 , then homogenized with Polytron for 30 sec at 4 o C and centrifuged at 30,000 g for 60 min. The supernatant was then collected and kept at 4 o C. The extract was chromatographed through an AcA54 gel filtration column equilibrated with 50 mM of Tris-Cl buffer containing 150 mM of NaCl. Obtaining enzyme profile, HNElastase-rich fractions were pooled, concentrated, and dialyzed against 50 mM of NaAc, pH 4.5, containing 150 mM NaCl.
Elastase-rich fraction prepared by Ultrogel AcA54 gel filtration was chromatographed again with a CM-Sephadex ion exchange column equilibrated with 50 mM NaAc buffer, pH 4.5, containing 150 mM of NaCl. Bound protein was eluted by a linear salt gradient (0.15-1 M) in the same buffer.
Elastase-rich fractions were pooled, concentrated, and dialyzed against 50 mM Tris-Cl, pH 4.5, containing 150 mM of NaCl. HNElastase purified by ion exchange chromatography was chromatographed again with CMSephadex ion exchange column equilibrated with 50 mM NaAc buffer, pH 4.5, containing 150 mM of NaCl. Bound protein was eluted by a linear salt gradient (0.3-0.8 M) in the same buffer. Four peaks of HNElastase were separated by this shallow gradient. Four peaks of HNElastase-rich fractions were collected separately, and each peak was pooled, concentrated, and dialyzed against 50 mM Tris-Cl containing 150 mM of NaCl, pH 7.3, labeled each peak as E-1, E-2, E-3, and E-4, then kept at -20 o C until use. The sample for Raman experiment was purified again from P-4 (least molecular weighted E4 elastase) by HPLC with TSK 250 gel filtration column equilibrated with 50 mM Tris-Cl containing 0.8 M of NaCl, pH 7.3. Finally purified HNElastase was analyzed by SDS-PAGE.
Elastase assay
Elastase assay was carried out in 200 µl of reaction medium (in 96-well microplate) containing 60-150 mM NaCl, 50 mM CaCl 2 , pH 7.3 with or without inhibitor depending upon the design of the experiment (Kang, 1985) . After 10-60 µl of elastase and substrate (SANA, 1-4 mM depend upon the design of experiment), was added to the reaction medium, then it was incubated at 37 o C for an appropriate period (usually 10-40 min depending on the nature of experiment). Elastase activity was measured spectrophotometrically at 410 nm by monitoring the concentration of liberated p-nitroaniline, using a Titertek Multiskan Spectrophotometer (MCC/ 340, Flow laboratories, Switzerland).
Preparation of drug bound elastase
Elastase-phenylbutazone complex was prepared by the previously described method (Kang, 1998) . Briefly, 500 µg of purified elastase was placed in 200 µg of 50 mM Tris buffer, pH 7.3, containing 5 mM CaCl 2 , 150 mM of NaCl, and 20% of dimethylsulfoxide (DMSO). After 24 µg of 0.5 mM phenylbutazone was added to the reaction medium containing HNElastase, then it was incubated at room temperature for 30 min. The mixture of drug and elastase sample was placed in Spectropore 2 membrane, then dialyzed three times against one liter of 50 mM Tris-Cl buffer, pH 7.3 at 4 o C. The dialyzed sample was frozen and kept at -20 o C until use.
Raman experiments
Raman spectra were recorded in melting point capillaries using Laser Raman Spectrophotometer System (Sepex 1403, 0.85m double spectrometer equipped by RCA-C 31034 phototube and DM 3000 software) (Kang, 1998) . All spectra were recorded using the 514.5-nm laser wavelengths for excitation. Data were collected at 1 cm −1 intervals with 0.3 s −1 integration time and 4 cm −1 spectral slit width.
Molecular modeling from crystallographic datum and sequence information
Two available crystallographic data files (Bode et al., 1986; Navia et al., 1989) of human neutrophil elastase were available from the Protein Data Bank (PDB) in Brookhaven National Laboratory, New York. The PDB covers atomic coordinates, structure factors and phases from different studies of macromolecules. In this description, we applied the Navia's PDB datum instead of Bode's since the Navia's PDB crystallographic datum was acquired from the elastase crystal crystallized after the activity was inhibited by a smaller molecular weight of inhibitor. The molecular model was constructed with a molecular visualization program (Roger Sayler Biomolecular Structure, Glaxo Research and Development, Greenford, Middlesex, UK) using Navia's PDB datum of crystallographic information of human neutrophil elastase. The details of specification of drawing each model was described in our previous paper (Kang, 1998) .
Results
Purification of four different HNElastase isozymes
Four elastase isozymes were separated effectively (usually not separated well) by three steps of purification procedure including Ultrogel AcA 54 gel filtration and two CM-Sephadex ion exchange chromatography (linear salt gradient 0.15-1 M and 0.3-0.8 M NaCl). Figure 1 showed the chromatography of CM-Sephadex ion exchange column eluted with shallow salt gradient. For the Raman experiments, the elastase isozyme (E-4) was chromatographed again by HPLC with TSK-250 gel filtration column and the peak4 was confirmed as a HNElastase isozyme, E-4 ( Figure 1B ). This HNElastase E-4 showed single band in SDS-PAGE ( Figure 1B ).
Inhibition of HNElastase by NSAIDs
Four different HNElastase isozymes (E-1, E-2, E-3, E-4), separated by CM-Sephadex ion exchange chromatography, were tested for inhibition of elastase activity. Figure 2 showed that four isozymes revealed different inhibition characteristics by various NSAIDs (drug concentration: 0.5 mM); i.e., E-1, E-2, and E-3 were inhibited well by ibuprofen, ketoprofen, naproxen, phenylbutazone, salicylic acid, and acetyl salicylic acid. However, E-4 was inhibited by ibuprofen, naproxen, and phenylbutazone, but not by ketoprofen, salicylic acid, and acetyl salicylic acid. Phenylbutazone (0.5 mM) inhibited all four HNElastase isozymes as much as about 50% of control activity, and the inhibition was concentration dependent manner up to 2 mM. Therefore, we employed phenylbutazone to investigate and explore the molecular pharmacological mechanism of the inhibition of NSAIDs.
Raman shift of HNElastase-phenylbutazone-complex
Binding of phenylbutazone to the human neutrophil elastase molecules was stable, and the HNElastasephenylbutazone complex was not dissociated during the sample mixture that was dialyzed to remove unbound phenylbutazone from the complex.
Raman spectra of HNElastase with or without binding of phenylbutazone are shown in Figure 3 . In Figure 3 , A, B, C, and D indicate the Raman spectra of control HNElastase, HNElastase-phenylbutazone complex, sus- ( Figure 3D ). Comparison of the Raman spectra of HNElastase ( Figure 3A ) with HNElastase-phenylbutazone complex ( Figure 3B ) showed similar contour but unique Raman shift bands between 200 and 1800 cm −1 . The new bands at 200, 440, and 1194 cm −1 appeared in the HNElastase-phenylbutazone complex ( Figure 3B ), but not in the control. Figure 3C is the Raman spectrum of freshly prepared mixture of elastase and phenylbutazone (without incubation, simply suspended in the reaction medium containing phenylbutazone) without dialysis. The contour of 3C is similar to that of control elastase (3A) but Raman bands are similar to that of the medium (3D). However, this spectrum ( Samples were scanned at wave number 1100-1800 cm −1 . Experimental details of preparation of the samples were described in the "Methods". Sample A and B were dialyzed against 50 mM Tris-Cl, pH 7.3. A, control elastase; B, human neutrophil HNElastase-phenylbutazone complex.
Discussion
Three step procedure includes Ultrogel AcA 54 gel filtration, CM-Sephadex ion exchange chromatography (linear salt gradient 0.15-1 M NaCl), and shallow salt gradient ion exchange chromatography (salt gradient 0.3-0.8 M NaCl). It is an effective method and the last step is an important step for purification and it is a new method ever reported for purification of HNElastase isozymes. Addition of dithiothretol (DTT, final concentration: 2 mM) to the mobile phase prevented aggregation or dimerization of the isozymes, and increased efficiency of purification and purity of the enzyme. For the Raman experiments, the four elastase isozyme, E-4 was purified by an additional step of purification by gel filtration column on HPLC equilibrated with 0.8 M NaCl. The enzyme was eluted in a single symmetrical peak ( Figure 1B) .
Four different HNElastase isozymes (E-1, E-2, E-3, E-4) that were partially purified by CM-Sephadex ion exchange chromatography with shallow salt gradient (0.3-0.8 M of NaCl) showed different elastase inhibition characteristics. Figure 2 showed that four isozymes revealed different inhibition characteristics by various NSAIDs(at constant drug concentration: 0.5 mM); i.e., E-1, E-2, and E-3 were inhibited well by ibuprofen, ketoprofen, naproxen, phenylbutazone, salicylic acid, and acetyl salicylic acid. However, E-4 was inhibited by ibuprofen, naproxen and phenylbutazone but not by ketoprofen, salicylic acid and acetyl salicylic acid. Drugs such as ibuprofen, ketoprofen, naproxen, phenylbutazone, salicylic acid, and acetyl salicylic acid inhibited HNElastase in concentration dependent manner. Ibuprofen, ketoprofen, naproxen, phenylbutazone showed partial competitive inhibition (data not shown). The molecular structure of HNElastase constructed by molecular visualization system and crystallographic data allowed to view a unique active site (Kang, 1998) . Molecular structural characteristics of HNElastase are; 1) the core area of elastase molecule was structurally stable, 2) the active site was at the core of the molecule, 3) the active center was in the deep pocket, 4) the rim of the pocket was surrounded by hydrophobic amino acids such as Phe170, Gly171, Phe25, Leu20, Val46, Tyr80, Pro82, and Leu85, 5) at the nearest neighboring area of active site, there were one positive charged atom (nitrogen atom of His41) and two negative charged atoms (sulfur atoms of Cys26 and Cys 42). The partial competitive inhibition by the drug molecules appeared to be derived from by an ionic interaction at an adjacent active site and partial covering up of the active site by hydrophobic interaction between the side chain of drug molecule and the hydrophobic amino acids surrounded the active site. The hydrophobicity may hinder free competition between inhibitor and substrate and it may cause a partial competitive inhibition. On the other hand, salicylic acid, and acetyl salicylic acid inhibited HNElastase competitively (data not shown). This competitive inhibition might come from pure classical competition between salicylate and substrate at the active site without hindrance of additional hydrophobic interaction. We, therefore, suggest that there must be two different classes of NSAIDs, i.e., elastase sensitive and insensitive drugs. Therefore, clinical application of the elastase sensitivity will be another important factor for the treatment of tissue destructive inflammatory disease and for the development of new drugs.
Phenylbutazone (0.5 mM) inhibited all four HNElastase isozymes effectively, and the inhibition was concentration dependent up to 2 mM. Therefore, we started to investigate the molecular pharmacological mechanism of the inhibition with phenylbutazone. Tolmetin and oxyphenbutazone were precipitated in our reaction medium containing DMSO (final concentration: 25%), preventing a further investigation on the inhibition characteristics under this medium condition.
Raman frequencies of HNElastase also undergo drastic changes upon binding of phenylbutazone. The differences between Figures A and B in Figures 3 and 4 must reflect the effects of the enzyme complex formation with phenylbutazone. In the elastase-phenylbutazone complex, the Raman shift at 1194 cm −1 could be the evidence of the two -N-Φ radicals of phenylbutazone molecule (Scheule et al., 1977 and 1979) . The bands at 1328 and 1418 cm −1 in the elastase-phenylbutazone complex may be related to the molecular structural conformational change by DMSO. Band 1382 cm −1 in the phenylbutazone-elastase complex ( Figure 4B ) may be related to the presence of pyrazole ring in the complex as seen in the crystal and aqueous samples of azocarboxypeptidase (Scheule et al., 1977 (Scheule et al., , 1979 (Scheule et al., , 1980 . Bands 1506, and 1588 cm −1 are new bands and may be related to the conformational change of carboxyl radical at an adjacent active site such as Asp88. Disappearance of 1404 may be related to the covering up of histidine ring at an area of active site (Lord, and Yu, 1970a shrunken by formation of drug-elastase complex. We speculated that Raman shifts between 1600 and 1800 cm −1 related to the conformational change especially by carboxyl radicals, but it needs detail study in the future. It has been known that human neutrophil elastase reacts with substrate at the active site as in the "Chargerelay" hypothesis of the mechanism of action of serine protease (Blow et al., 1969) . The corresponding amino acids are Ser173, Asp88, and His41, and positive charge will be relayed from hydrogen atom of Asp88 through His41 to Ser173. When we apply this classical mechanism of action to our experimental results, the inhibitory effects of human neutrophil elastase must be related to the property of the drug binding to the active site of the elastase such as complete or partial masking of the active site ( Figure 5) (Kang, 1998) . In phenylbutazone inhibition, both -C=O δ− portions and nitrogen atoms of the pyrazole ring in the phenylbutazone molecule might be important factors for the binding of phenylbutazone molecule to the active site of the human neutrophil elastase molecule ( Figure 6A ). The negative charged oxygen atoms in the -C=O δ− portion of pyrazole ring may interact with the weak positive charged nitrogen atoms of the histidine ring of the active site ( Figure 5 ). As one can see in the molecular models constructed by the crystallographic PDB data in previous paper (Kang, 1998) , active sites of human neutrophil elastase showed important molecular structural factors; 1) the vicinity of the active site of human neutrophil elastase is surrounded by hydrophobic amino acids such as Phe, Gly, Leu, Val, Pro, and Leu, 2) one positive charged atom (nitrogen atom of His) and two negative charged atoms (sulfur atoms of Cys26 and Cys 42) at near the active site formed rigid conformation ( Figure 6B ). Therefore, three weak charged atoms might be bound electrostatically to the corresponding opposite charge of the phenylbutazone molecule, i.e., one of the two negative charged C=O δ− and two positive charged -N+ in the pyrazole ring of the phenylbutazone molecule ( Figure 6B ), leading to a strong interaction between the drug and enzyme. Phenylbutazone may form key and lock like binding to the atoms charged with opposite charge near the active site of enzyme molecule. Furthermore, the surrounding hydrophobic amino acid molecules of enzyme will also interact very effectively with the hydrophobic parts of the phenylbutazone such as benzene rings and aliphatic carbon chain. Binding of phenylbutazone to an area near the active site of human neutrophil elastase may cause masking of the active site with drug preventing the substrate from approaching the active site, possibly inhibiting the elastase activity. The interaction of the drug molecule to the active site by hydrophobicity will hinder the free competition between phenylbutazone and substrate, and as the result, phenylbutazone may inhibit HNElastase by partial competition. This result can also be applied to the development of new drug design.
In conclusion, the inhibitory effect of elastase could be, besides inhibition of cyclooxygenase, an another important mechanism of action of NSAIDs including aspirin, salicylate, and phenylbutazone in the treatment of inflammatory diseases. The mechanism of the elastase inhibition may be related to the specific molecular struc- ture of elastase and NSAIDs such as phenylbutazone, and the charged portion and hydrophobicity must be important factors for the drug binding to the active site of human neutrophil elastase.
